Introduction
Rheumatoid arthritis (RA) is a chronic joint disease leading to severe erosions of adjacent bone, which are not observed in patients with osteoarthritis (OA). Although an inflammatory process is present in OA synovial tissue, RA patients demonstrate a higher state of synovial tissue inflammation compared with OA patients. In the pathophysiology of RA, T cells, B cells, macrophages, fibroblasts, and osteoclasts play dominant roles. In addition, neutrophils are important mediators of tissue inflammation in RA, and neutrophils are the most abundant cell type in the synovial fluid [1] . Neutrophil production of proteases, reactive oxygen species, S100 proteins, cytokines, chemokines, and complement stimulate inflammation [2] . Fc-gamma receptors on neutrophils can bind immune complexes that can perpetuate the inflammatory process [2] . In addition, neutrophils produce important antimicrobial proteins, such as defensins [3] .
A large number of defensins and defensin-like peptides have been reported in many organisms. As of March 2010, 363 entries had been recorded in a defensin database [4] . One distinguishes α-defensins (in neutrophils) from β-defensins (in other cells). Human neutrophils contain four α-defensins (HNP-1 to HNP-4) [5] . HNPs are unique to neutrophils and account for ~99% of the total α defensin content of these cells [5] . HNPs exert chemotactic, immunomodulating, and cytotoxic effects and participate in inflammation [5] . In contrast, human β-defensins have been described mainly in epithelial cells but also in leukocytes, heart, skeletal muscle, testis, keratinocytes, tonsil, placenta, and other tissues [4] . Defensins are expressed and released on bacterial stimuli involving the Toll-like receptors and, in addition, other stimuli, such as cytokines [6] . Besides microbicidal activities, defensins can stimulate TNF secretion from macrophages, as recently reported [7] .
In tissues of patients with RA and OA, the investigation of defensins has recently begun. One report demonstrated the presence of HNP1 3 positive cells in synovial tissue of healthy subjects and in patients with suppurative arthritis, osteoarthritis (OA), and RA [8] . However, regulation of HNP1-3 in these diseases (for example, by cytokines) has not yet been investigated. Another report found an association of HNP1-3 in synovial fluid of patients with RA and severe erosive joint disease [9] . These studies clearly demonstrate that neutrophil defensins are present in inflamed tissues of patients with RA and OA. Some reports also demonstrated that defensins can be produced by dendritic cells and monocytes [10, 11] , but this has not been demonstrated in synovial tissue or cells of RA and OA patients.
For several years, we have been interested in the role of the sympathetic nervous system (SNS) in OA, RA, and experimental arthritis [12, 13] . We have been attracted by effects of the SNS on neutrophils and monocytes, but effects on defensin secretion are presently not known. It is recognized that activation of the SNS enhances neutrophil and monocyte mobilization, leading to increased numbers of circulating neutrophils and monocytes, called the first line of defense [14] [15] [16] . Such a mechanism might increase the numbers of neutrophils and monocytes that enter inflamed tissue at sites of leaky endothelial structures (leakiness is important because catecholamines inhibit neutrophil and monocyte attachment to normal endothelium). However, once neutrophils and monocytes have entered inflamed tissue, the major neurotransmitter of sympathetic nerve fibers, norepinephrine, inhibits several neutrophil and monocyte functions. For example, norepinephrine decreases migration [17, 18] , oxygen radical production [19] , phagocytosis [18] , and bactericidal activity [20] . These inhibitory influences were present only when norepinephrine appeared at high concentrations (via β 2 -adrenergic receptors). This might be quite different at low concentrations when norepinephrine exerts its effects via α-adrenoceptors [21] [22] [23] .
Thus, in the presence of sympathetic nerve fibers in the tissue, norepinephrine would inhibit many proinflammatory activities of neutrophils and monocytes via β 2 -adrenoceptors, which might also play a role in synovial tissue of patients with OA and RA. However, in inflamed synovial tissue of patients with RA, sympathetic nerve fibers are lost and replaced by catecholamine-producing cells [24] . The remaining catecholamine concentrations are low in the synovial tissue, leading to concentrations suitable only for α-adrenergic signaling [24] . Although norepinephrine through α-adrenergic signaling stimulates proinflammatory factors in neutrophils and macrophages [21] [22] [23] , these low concentrations may well play a proinflammatory role in inflamed tissue.
By using synovial cells of patients with RA, we investigated the effect of norepinephrine on abundance of the proinflammatory bactericidal proteins HNP1-3. Experiments were also carried out in cells from OA patients because possible differences might represent one factor for the differential effects on bone (erosions in RA versus formation of new bone in OA). For comparison, we investigated the human defensin β-defensin 2 (HBD 2). TNF was used as another important proinflammatory stimulus to influence defensin secretion for comparison. In addition, the study aimed to investigate the influence of cortisol alone or together with norepinephrine because cooperative antiinflammatory effects of cortisol and norepinephrine have been described [25] .
Materials and methods

Patients
In this investigation, we included 10 patients with OA and seven patients with RA. Diagnosis of RA was based on the established criteria according to the American College of Rheumatology (formerly, the American Rheumatism Association) [26] . The characteristics of patients are given in Table 1 . Erythrocyte sedimentation rate and serum levels of C-reactive protein were measured by using standard techniques.
The study was approved by the Ethics Committee of the University of Regensburg. Patients were informed about the purpose of the study and gave written consent.
Synovial tissue preparation, isolation, and culture of primary mixed synovial cells OA and RA patients underwent elective knee-joint replacement surgery. Synovial tissue samples were obtained immediately after opening the knee-joint capsule, preparation of which was described [24] . In brief, a piece of synovial tissue of ≤9 cm 2 was dissected. A larger piece of the synovial tissue was used to isolate mixed synovial cells (for culture experiments, see later). Approximately eight pieces of the same synovial area were used for immunohistochemistry and immunofluorescence, which were fixed for 12 to 24 hours in phosphate-buffered saline (PBS) containing 4% formaldehyde and then incubated in PBS with 20% sucrose for 12 to 24 hours. Thereafter, they were placed in protective freezing medium and quick-frozen (Tissue Tek; Sakura Finetek, Zoeterwoude, The Netherlands). All tissue samples were stored at 80°C.
For culture experiments, mixed synovial cells were isolated during the morning hours by enzymatic digestion for 1 to 2 hours at 37°C by using Liberase (Roche Applied Science, Mannheim, Germany). At approximately 2 to 4 p.m., the synovial cells were resuspended in RPMI 1640 medium (Sigma, Taufkirchen, Germany), supplemented with 1% penicillin/streptomycin (Life Technologies, Inc., Paisley, U.K.) and 0.1% amphotericin B (Bristol-Myers Squibb, Munich, Germany). In total, 2.5 × 10 5 isolated synovial cells of OA or RA patients were incubated for 24 hours in the presence of 200 μM L-ascorbic acid, together with norepinephrine, TNF, cortisol, or norepinephrine plus cortisol in indicated concentrations (all substances from Sigma, Steinheim, Germany).
The percentage of different types of synovial cells was tested by specific antibodies against prolyl 4 hydroxylase (for the synoviocyte type B, fibroblasts; Calbiochem, Bad Soden, Germany), CD163 (synoviocyte type A, macrophages; Dako, Hamburg, Germany), CD3 (T cells; Dako), CD19 (B lymphocytes; Dako) neutrophils (elastase; Fitzgerald Industries Int. Inc., Acton, MA, USA), and mast cells (tryptase; Abcam, Cambridge, UK).
In preliminary experiments with primary early-culture mixed synoviocytes, we detected that ~37% were positive for prolyl 4 hydroxylase, 26% for CD163, 12% for CD3, 5% for CD19, 10% for elastase, and <1% for tryptase.
Immunohistochemistry and double immunofluorescence
Approximately ten 5-μm sections were cut from the frozen tissue blocks. For immunohistochemistry with alkaline phosphatase as the enzyme system, sections were blocked with 20% acetic acid for 20 minutes at 4°C. Sections were further blocked with 10% bovine serum albumin, 10% fetal calf serum, and 10% chicken serum for 45 minutes (all from Sigma). Then, sections were incubated with either monoclonal mouse anti-human antibodies against HNP1-3 (BMA Biomedicals, Augst, Switzerland, no. T 1034; dilution, 1:1,000; these antibodies recognize HNP-1 to -3) or polyclonal rabbit anti-human antibodies against HBD-2 (Biologo, Kronshagen, Germany, no. DEF002; dilution, 1:100). Both primary antibodies were incubated overnight at 4°C. After intensive washing with phosphate-buffered saline, sections were incubated with secondary antibodies for 1 hour at room temperature (for HNP1-3, goat anti-mouse coupled to alkaline phosphatase; Dako, no. D0486; dilution, 1:100; for HBD-2, goat anti-rabbit coupled to alkaline phosphatase, Dako, no. D0487; dilution, 1:100). The sections were developed by using BCIP/NBT substrate (Dako, K0598). We controlled specific staining by using irrelevant primary antibodies or serum or by omitting the primary antibody.
Double immunofluorescence was carried out with fixed frozen tissue and a similar blocking procedure to that 
Determination of HNP1-3 and HBD-2 in supernatants of synovial cells
HNP1-3 were measured with commercially available ELISA (HyCult Biotechnology, Uden, The Netherlands; this ELISA recognizes HNP-1 to -3). The detection limit of this assay was 20 pg/ml. Intra-and interassay coefficient of variation were <10%. With respect to HBD-2, a new ELISA was established by using two commercially available antibodies (capture: Biologo, no. DEF002, polyclonal rabbit anti-human antibodies; dilution, 1:1,000; detection, R&D Systems, Wiesbaden, Germany; AF2758, polyclonal goat anti-human antibodies; dilution, 1:200). After overnight coating with the capture antibody at 4°C, extensive washing, and blocking with 10% fetal calf serum, 100 μl of standard (recombinant HBD-2; Dianova, Hamburg, Germany, no. CYT-26732) or 100 μl supernatant of synovial cells was incubated for 2 hours at room temperature. After extensive washing, the detection antibody was added for another hour (at room temperature). After extensive washing, a rabbit anti-goat tertiary antibody was used, coupled to biotin (Dako, Hamburg, Germany; no. E0466). By using streptavidin coupled to horseradish peroxidase and tetramethylbenzidine (TMB) as the substrate, the ELISA was developed. The detection limit of this assay was ~8 pg/ml. Intra-and interassay coefficients of variation were <15%.
Superfusion technique of synovial tissue
As described in detail earlier [24] , we used a microsuperfusion-chamber apparatus to superfuse pieces of synovial tissue with culture medium. This technique allows the determination of spontaneous defensin release directly from fresh synovial tissue. The superfusion chambers had a volume of ~80 μl. Super-fusion was performed for 6 hours at a tempera-ture of 37°C and a flow rate of 66 μl/ min. Synovial tissue pieces had a standard size of 5 μm in diameter with a precision biopsy punch (Stiefel, Offenbach, Germany). Every hour, superfusate was collected to measure HNP1-3 and HBD-2, as described earlier.
Presentation of the data and statistical analysis
All data are given as mean ± SEM. Box plots give the 10 th , 75 th , 50 th (median), 25 th , and 10 th percentile. Group medians were compared by using the nonparametric MannWhitney test (SPSS/PC, Advanced Statistics, V15.0, SPSS Inc., Chicago, IL, USA). A value of P < 0.05 was the significance level.
Results
Immunohistochemical localization of HNP1-3 and HBD-2 and double immunofluorescence
To study the localization of defensins, immunohistochemistry of the synovial lining and sublining area was performed in patients with OA and RA. A representative staining of an RA patient is given in Figure 1 . HNP1 3 were detected mainly in the synovial lining and in the directly adjacent sublining area (Figure 1, left panels) . HNP1-3 were present in most of the RA patients and OA patients. This was quite different for HBD-2, which was rarely detectable in RA and OA patients. The staining in Figure 1 , right panels, is a rare example of an RA patient in whom HBD-2-positive cells were detected in the sublining zone.
In further extensive double immunofluorescence studies, we provide evidence that HNP1-3 were colocalized to elastase-positive neutrophils (Figure 2, left panels) . HNP1-3 were not detected in macrophages, fibroblasts, T lymphocytes, B lymphocytes, or mast cells. Similar to that in immunohistochemistry, HBD-2 was rarely detected with immunofluorescence. In these cases, HBD-2 was colocalized with prolyl-4 of fibroblasts and CD19 of B lymphocytes (Figure 2, right panels) . No similar colocalization was observed for macrophages, T lymphocytes, neutrophils, or mast cells.
HNP1-3 and HBD-2 from synovial tissue and synovial cells
To study the release of HNP1-3 or HBD-2, the protein was detected in the superfusate of synovial tissue. Synovial tissue released HNP1-3, which was particularly evident in RA patients ( Figure 3A) . The slow decline of superfusate concentration is typical for a washout of the protein and not for a decrease in secretion or production (Figure 3a) . Compatible with the findings in immunohistochemistry, HBD-2 superfusate levels were lower, as substantiated in RA and OA patients (Figure 3b) .
On a very different time scale, levels of defensins were studied in supernatants of cultured mixed synovial cells (Figure 3c ). The levels of HNP1-3 increased over time, whereas HBD-2 was barely detectable (Figure 3c , compare detection limits with those in Figure 3a, b) . Because HNP1-3 were detectable by ELISA, further functional studies included only these peptides. We studied early HNP1-3 appearance within 24 hours to minimize a possible effect by necrosis or apoptosis of these cells.
Density of neutrophils in synovial tissues of patients with OA and RA
The presence of HNP1-3 prompted us to study the density of elastase-positive neutrophils in synovial tissues of patients with OA and RA. The density of neutrophils was higher in RA as compared with OA patients (Figure 3d ). The relatively low density of neutrophils is due to the fact that neutrophils were present mainly in the lining and adjacent sublining area but not in deeper layers of the synovial tissue, which were also considered in calculating tissue density (see legend in Figure 3d) .
Influence of TNF, norepinephrine, and cortisol on levels of HNP1-3
To study important factors that might influence HNP1-3 levels, such as proinflammatory cytokines like TNF, this cytokine was used in culture experiments with mixed synoviocytes. TNF slightly decreased HNP1-3 levels in the supernatant of OA cells, which was significant at 1 ng/ml (Figure 4) . In RA synoviocytes, TNF did not exert a similar U-formed dose-response effect because no significant differences were observed (Figure 4) .
In contrast, norepinephrine decreased supernatant HNP1-3 levels produced by mixed synovial tissue cultures in both OA and RA patients (Figure 5a, b) . It is obvious that this inhibition was present only at high concentrations when norepinephrine exerts its effects mainly via β-adrenoceptors (Figure 5a, b) .
In OA patients, cortisol at high concentrations of 10 -6 M reduced HNP1-3 concentrations (Figure 5c ), which was not observed in RA patients (Figure 5d ). In addition, the combination of cortisol plus norepinephrine led to a decrease of HNP1-3 levels produced by mixed synovial tissue cultures in OA and also in RA patients (Figure 5c,  d) . However, the combined effect of the two hormones did not exceed the individual effects of norepinephrine alone.
Discussion
This study demonstrates the presence of two human defensins in the synovial tissue of patients with OA and RA. The α-defensin HNP1-3 and the β-defensin HBD-2 were present in synovial tissue, whereas HNP1-3 was undoubtedly allocated to neutrophils (we have not tested for dendritic cells). HBD-2 was found in a small number of fibroblasts and B lymphocytes. Although HNP1-3 were easily detectable by using histologic techniques or in culture experiments, HBD 2 was barely visible in tissue and measurable in supernatants. This study further demonstrated that norepinephrine inhibited HNP1 3 in both RA and OA patients' mixed synovial cell cultures, and cortisol and TNF slightly inhibited this α-defensin only in OA patients. This investigation adds to the understanding of how the SNS might influence HNP1-3 in chronic inflammatory joint diseases. 1-3 (HNP1-3) of mixed synoviocytes. The data are derived from five OA and five RA patients (two replicates of every patient). Control HNP1-3 levels were 58.3 ± 7.0 pg/ml in OA patients and 147.2 ± 37.5 pg/ml in RA patients. The data are derived from nine OA and seven RA patients (three replicates of every patient). Control HNP1-3 levels were 160.2 ± 50.3 pg/ml in OA patients and 73.5 ± 19.9 pg/ml in RA patients.
In a previous report, the presence of HNP1 3-positive cells was demonstrated in the synovial lining of healthy subjects and in patients with suppurative arthritis, OA, and RA [8] . However, these authors did not study the regulation of HNP1-3, which was a particular aspect in the present work. Another study reported very high synovial fluid levels of HNP1 3 in RA patients, associated with more-severe erosions [9] . Because we used the same ELISA mentioned in the latter study, we were surprised that our superfusate and supernatant levels of HNP1-3 were lower. We interpret these earlier findings of Bokareva et al. [9] insofar as HNP1-3 accumulate in the synovial fluid, which has been demonstrated for other factors as well (for example, estrogens [27] ). Because we have not studied synovial fluid levels, we cannot directly compare the results of the two studies. However, discrepant findings might also depend on increased abundance of neutrophils in synovial fluid, as compared with synovial tissue.
Although HNP1-3 defensins have been reported to be expressed by granulocytes in synovial tissue [8] , it was not clear whether these proteins are actually released in the tissue. By using the superfusion approach, we were able to demonstrate that these proteins are released by few granulocytes in synovial tissue. In the present study, HNP1-3 is produced in higher amounts in RA than in OA, which might reflect the overall greater inflammation in patients with chronic RA. This is particularly relevant because RA patients were treated with prednisolone and antiproliferative drugs that should have reduced proinflammatory factors like HNP1-3. HNP1-3-positive cells were elastase-positive neutrophils, and we can exclude that other cells such as macrophages, fibroblasts, T and B lymphocytes, or mast cells stain positive for this protein.
However, we have not tested dendritic cells that can also produce HNP1-3 [10, 11] . The relatively low number of neutrophils in the tissue might be a consequence of rapid migration into the synovial fluid (>95% are neutrophils).
The mentioned first study of Paulsen et al. also reported on HBD-2 [8] , which was not found in their samples investigated (they found the defensins HBD-3, CAP37, and LL37). We confirmed that immunohistologic detection of HBD-2 is a rare event (found in only one patient with RA and in one with OA). Nevertheless, this RA patient had numerous positive cells that allowed double staining, revealing double-positive fibroblasts and B lympho-cytes. Because HBD-2 levels were below the detection limit in most superfusate and supernatant samples, functional experiments with TNF and hormones aimed only to investigate the α-defensin HNP1-3. Further studies corroborated that neutrophils are present in OA and RA tissue, and that the density of these cells is higher in RA than in OA patients. It is known that the SNS has a strong influence on neutrophils (but also on monocytes), so we were particularly interested in the functional effects of the SNS on HNP1-3.
The major neurotransmitter of sympathetic nerve fibers, norepinephrine, inhibits several cellular functions. For example, norepinephrine decreases migration [17, 18] , oxygen radical production [19] , phagocytosis [18] , and bactericidal activity [20] . These inhibitory influences on neutrophils (but also on monocytes) were present only when norepinephrine appeared at high concentrations (via β 2 -adrenergic receptors). This might be quite different at low concentrations, when norepinephrine exerts its effects via α-adrenoceptors [21] [22] [23] . Our present study supports the inhibitory influence of norepinephrine, focusing on the α-defensin HNP1-3. In both RA and OA patients, norepinephrine dose-dependently decreased supernatant levels of HNP1-3 from mixed synovial tissue cultures, which reached the significance level only at high concentrations. These norepinephrine effects were stronger when compared with cortisol alone, which did not influence HNP1-3 in RA synovial cells. In addition, the combination of norepinephrine plus cortisol did not materialize in an additive or even synergistic effect. These results confirm the overall inhibitory effect of norepinephrine on cellular functions, given that concentrations of this neurotransmitter are high enough. At low concentrations of 10 -9 M norepinephrine, we did not observe opposite effects that would indicate a proinflammatory influence on mixed synovial tissue cultures via α-adrenoceptors.
Because TNF is an important proinflammatory molecule in chronic inflammatory joint diseases, the effect of this cytokine on HNP1-3 levels was tested in this study. It was known that β-defensins such as HBD-2 can be stimulated by TNF in epithelial cells and astrocytes [28, 29] , but, to our knowledge, effects of TNF on HNP1-3 were not investigated (especially not in OA/RA material). TNF decreased HNP1-3 supernatant levels in OA mixed synovial cultures, and the dose-response curve was Ushaped with a maximum inhibition at 1.0 ng TNF/ml. TNF did not exert similar effects in RA cell cultures, which may be related to already high TNF levels in these cell preparations (receptor desensitization). Because, conversely, HNP1-3 can stimulate TNF secretion from macrophages, as recently reported [7] , the TNF-induced inhibition of HNP1-3 might be part of a negative-feedback loop that prevents overshooting of innate immune responses. From this point of view, we hypothesize that HNP1-3 precedes TNF in the stimulatory cascade of innate immunity events. This would be an important aspect because TNF has been installed at the forefront of the innate immunity cascade in RA [30] .
Conclusions
In conclusion, HNP1-3 is present in neutrophils, and as compared with HBD-2, it is abundantly present in chronically inflamed synovial tissue of patients with RA and OA. Because HNP1-3 levels are decreased by norepinephrine in mixed synovial-cell cultures, this study demonstrates that the SNS might inhibit neutrophil (but also monocyte) function in vivo. Sympathetic nerve fibers are lost in inflamed tissue [24, 31] , so concentrations of this neurotransmitter are probably too low to induce antiinflammatory activities. A similar situation exists for TNF, which is also decreased by norepinephrine [32] . HNP1-3 can stimulate secretion of TNF [7] , so the loss of sympathetic nerve fibers with low concentrations of norepinephrine might have double-negative effects, possibly increasing both local HNP1-3 and TNF levels. This scenario can be relevant in overt inflammation of the tissue when monocytes (HNP1-3, TNF), macrophages (TNF), and neutrophils (HNP1-3) play a decisive role.
